View Document Preview and Link Document Date: 2013-07-29 16:00:10 Open Document File Size: 356,33 KB Share Result on Facebook
City Mississauga / / Company GlaxoSmithKline Inc. / B01AX05 Synthetic Antithrombotic GlaxoSmithKline Inc. / / Event FDA Phase / / IndustryTerm injection site / dry natural latex rubber / / MedicalCondition PE Moderate thrombocytopenia / subsequent myocardial infarction / ST segment elevation myocardial infarction / abdominal surgery Thrombocytopenia / active ulcerative gastrointestinal disease / Acute bacterial endocarditis / intracranial hemorrhage / Carcinogenesis / catheter thrombus / non-ST segment elevation myocardial infarction / Thrombocytopenia / abdominal cancer / severe renal insufficiency / severe hepatic insufficiency / Renal Insufficiency / unstable angina / Severe thrombocytopenia / permanent paralysis / catheter thrombosis / Latex Allergy / allergic reactions / acquired bleeding disorders / Acute Deep Vein Thrombosis / deficiency / mild renal insufficiency / moderate renal insufficiency / peri-procedural myocardial infarction / Hepatic Insufficiency / Thrombocytopenia Thrombocytopenia / / MedicalTreatment reperfusion therapy / orthopedic surgeries / catheter / cancer surgery / orthopedic surgery / catheters / hip replacement surgery / hip replacement / abdominal surgeries / knee surgery / surgery / abdominal surgery / / Organization DOSAGE AND ADMINISTRATION / / Position Peri-Operative / WARNINGS AND PRECAUTIONS General / / Product sodium chloride / ARIXTRA / vitamin K / Strength Nonmedicinal Ingredients Subcutaneous Injection / 6L4 / ARIXTRA® / / ProvinceOrState Prince Edward Island / Ontario / / Technology Geriatrics / pharmacokinetics / / SocialTag 
Microsoft Word - Arixtra_PM _2013-07-12_.doc